Kenneth Villman

Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Heikki Joensuu, Judith Fraser, Hans Wildiers et al. · JAMA Oncology · 2018 · 149 citations · Full text

Medicine, Oncology, Pharmacology +17

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · Journal of Clinical Oncology · 2011 · 118 citations · Full text

Medicine, Oncology, Pharmacology +17

Expression of Ephb2 and Ephb4 in breast carcinoma

Qinghua Wu, Zhenhe Suo, Bjørn Risberg et al. · Pathology & Oncology Research · 2004 · 109 citations

Medicine, Molecular Biology, Oncology +11

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer

Heikki Joensuu, Pirkko‐Liisa Kellokumpu‐Lehtinen, Riikka Huovinen et al. · JAMA Oncology · 2017 · 95 citations · Full text

Medicine, Oncology, Pharmacology +17

Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer

Juliane Baumgart, Kerstin Nilsson, Anneli Stavreus‐Evers et al. · American Journal of Obstetrics and Gynecology · 2010 · 90 citations

Medicine, Oncology, Urology +16